Looking for ways to measure tumour aggression
Tests show an association between how aggressive a tumour is and the levels of sugar and inflammatory proteins in the blood.
Selangor, Malaysia - (ACN Newswire) - Researchers...
Sino Biopharmaceutical Announces 2018 Third Quarterly Results
Profit Attributable to the Group Increased by Approximately 29.9% to Approximately RMB 2,247,477,000
HONG KONG - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the...
OIC Medicines Authorities committed to cooperating toward Safe, Efficacious and Standardized Medicines and Vaccine...
- First Meeting of OIC NMRAs concludes in the Jakarta Declaration
JAKARTA - (ACN Newswire) - The heads of National Medicines Authorities (NMRA) from the Organization of Islamic...
Innovent HK IPO gains wide support from international investors; Spearheads in cancer treatment breakthroughs
HONG KONG - (ACN Newswire) - Chinese biologic drug developer Innovent Biologics (Innovent) becomes the 4th pre-revenue biotech firm to list in Hong Kong yesterday. The seven-year-old...
Innovent Biologics Gets Listed Today; Long-term Bullish Performance Anticipated
HONG KONG - (ACN Newswire) - Innovent Biologics , a China Suzhou-based biopharmaceutical company, completes its initial public offering in Hong Kong, with trading officially...
Innovent Biologics Gets Listed Today; Long-term Bullish Performance Anticipated
HONG KONG - (ACN Newswire) - Innovent Biologics , a China Suzhou-based biopharmaceutical company, completes its initial public offering in Hong Kong, with trading officially commencing today....
Microbiome – The Next Frontier in Medicine
HONG KONG - (ACN Newswire) - Earlier this year the Hong Kong Exchange updated its listing rules to include pre-revenue biotech stocks for the first...
Ascletis Successfully Listed on the Main Board of HKEX
HONG KONG - (ACN Newswire) - Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital...
Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA
Hangzhou and Shaoxing, China - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir...
Ascletis-developed Ganovo Acquired Extraordinary Achievement
Ganovo Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association
HONG KONG - (ACN Newswire) - Ascletis announced on...
